Received Feb 12, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
Vaccine exposure during pregnancy; pregnant patient received Arexvy vaccine; This non-serious prospective pregnancy case was reported by a pharmacist via sales rep and described the occurrence of vaccine exposure during pregnancy in a female patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On 03-FEB-2026, the patient received the 1st dose of Arexvy (unknown arm). On an unknown date, an unknown time after receiving Arexvy, the patient experienced vaccine exposure during pregnancy (Verbatim: Vaccine exposure during pregnancy) and product use in unapproved population (Verbatim: pregnant patient received Arexvy vaccine). The outcome of the vaccine exposure during pregnancy and product use in unapproved population were not applicable. Pregnancy exposure: Pregnancy Exposure (Arexvy): To mother in third trimester Pregnancy Outcome: Pregnancy was ongoing Additional Information: GSK receipt date: 06-FEB-2026 Pregnant patient (35 weeks) received respiratory syncytial virus vaccine in retail pharmacy after recommendation from obstetrician. Patient returned to outpatient pharmacy questioning the product administered. Pharmacist reporting the adverse drug reaction believes it was confirmed that patient was given Arexvy, but was not certain. The batch number was not provided, and we are unable to contact the reporter.